1211534-87-0Relevant academic research and scientific papers
Key intermediate of 6,7,8,9-tetrahydro-5H-pyridino [2,3-d]azepine, and preparation method
-
Paragraph 0093; 0121; 0122; 0123, (2018/07/15)
The invention discloses a key intermediate (a compound I) of 6,7,8,9-tetrahydro-5H-pyridino [2,3-d]azepine, as well as a preparation method and application thereof. The method comprises the followingsteps of adopting 2,3-di (chloromethyl)pyridine (a compound II) as a raw material, and carrying out cyanation reaction to obtain a compound III; carrying out hydrolysis esterification to obtain the compound I; reducing the compound I to obtain a compound IV; carrying out reaction on the compound IV and acyl chloride to obtain a compound V; carrying out ring closing reaction on the compound V and an ammonia reagent to obtain the 6,7,8,9-tetrahydro-5H-pyridino [2,3-d]azepine (a compound VI).
NOVEL PYRAZOLOPYRIMIDINES
-
Paragraph 0117; 0118, (2013/10/08)
This invention relates to novel pyrazolopyrimidines and their use as metabotropic glutamate 5 receptor antagonists (mGlu5 receptor antagonists), pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of mGlu5 receptor mediated disorders.
NOVEL PYRAZOLOPYRIMIDINES
-
Page/Page column 23, (2013/10/21)
This invention relates to novel pyrazolopyrimidines and their use as metabotropic glutamate receptor antagonists (mGlu5 receptor antagonists), pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of mGlu5 receptor mediated disorders.
